[KLCC] YoY TTM Result on 30-Sep-2018 [#3]

Stock
[KLCC] KLCC PROP&REITS-STAPLED SEC
Announcement Date
13-Nov-2018
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
30-Sep-2018 [#3]
Profit Trend
QoQ- 0.42%
YoY- 0.83%
Quarter Report
Latest QR
Upcoming QR
KLCC's Result
KLCC's Financial Summary
View:
Show?
TTM Result
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
Revenue 1,127,592 1,299,404 1,424,408 1,391,665 1,359,368 1,346,001 1,340,085 -2.83%
PBT 457,101 954,018 971,808 1,123,954 1,098,664 1,546,134 1,270,158 -15.64%
Tax -54,740 -110,534 -127,228 -98,944 -92,465 -111,130 -110,217 -11.00%
NP 402,361 843,484 844,580 1,025,010 1,006,199 1,435,004 1,159,941 -16.16%
-
NP to SH 383,688 718,415 729,400 886,769 879,512 1,162,192 940,056 -13.86%
-
Tax Rate 11.98% 11.59% 13.09% 8.80% 8.42% 7.19% 8.68% -
Total Cost 725,231 455,920 579,828 366,655 353,169 -89,003 180,144 26.10%
-
Net Worth 13,070,611 13,196,984 13,124,771 13,070,610 12,835,917 12,601,224 12,077,677 1.32%
Dividend
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
Div 500,077 630,061 673,389 658,043 643,601 643,059 606,230 -3.15%
Div Payout % 130.33% 87.70% 92.32% 74.21% 73.18% 55.33% 64.49% -
Equity
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
Net Worth 13,070,611 13,196,984 13,124,771 13,070,610 12,835,917 12,601,224 12,077,677 1.32%
NOSH 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 1,805,333 0.00%
Ratio Analysis
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
NP Margin 35.68% 64.91% 59.29% 73.65% 74.02% 106.61% 86.56% -
ROE 2.94% 5.44% 5.56% 6.78% 6.85% 9.22% 7.78% -
Per Share
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
RPS 62.46 71.98 78.90 77.09 75.30 74.56 74.23 -2.83%
EPS 21.25 39.79 40.40 49.12 48.72 64.38 52.07 -13.86%
DPS 27.70 34.90 37.30 36.45 35.65 35.62 33.58 -3.15%
NAPS 7.24 7.31 7.27 7.24 7.11 6.98 6.69 1.32%
Adjusted Per Share Value based on latest NOSH - 1,805,333
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
RPS 62.46 71.98 78.90 77.09 75.30 74.56 74.23 -2.83%
EPS 21.25 39.79 40.40 49.12 48.72 64.38 52.07 -13.86%
DPS 27.70 34.90 37.30 36.45 35.65 35.62 33.58 -3.15%
NAPS 7.24 7.31 7.27 7.24 7.11 6.98 6.69 1.32%
Price Multiplier on Financial Quarter End Date
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
Date 30/09/21 30/09/20 30/09/19 28/09/18 29/09/17 30/09/16 30/09/15 -
Price 6.49 7.72 8.07 7.60 8.00 7.72 7.00 -
P/RPS 10.39 10.73 10.23 9.86 10.62 10.35 9.43 1.62%
P/EPS 30.54 19.40 19.97 15.47 16.42 11.99 13.44 14.64%
EY 3.27 5.15 5.01 6.46 6.09 8.34 7.44 -12.79%
DY 4.27 4.52 4.62 4.80 4.46 4.61 4.80 -1.92%
P/NAPS 0.90 1.06 1.11 1.05 1.13 1.11 1.05 -2.53%
Price Multiplier on Announcement Date
30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 30/09/15 CAGR
Date 08/11/21 10/11/20 11/11/19 13/11/18 13/11/17 03/11/16 11/11/15 -
Price 6.75 7.72 7.99 7.66 7.77 7.80 7.00 -
P/RPS 10.81 10.73 10.13 9.94 10.32 10.46 9.43 2.30%
P/EPS 31.76 19.40 19.78 15.59 15.95 12.12 13.44 15.39%
EY 3.15 5.15 5.06 6.41 6.27 8.25 7.44 -13.33%
DY 4.10 4.52 4.67 4.76 4.59 4.57 4.80 -2.59%
P/NAPS 0.93 1.06 1.10 1.06 1.09 1.12 1.05 -2.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment